Amedisys Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys or view top-rated stocks.

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amedisys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Amedisys.

Amedisys, Inc. (NASDAQ:AMED) issued its quarterly earnings data on Wednesday, August, 4th. The health services provider reported $1.69 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.02. The health services provider earned $564.17 million during the quarter, compared to the consensus estimate of $565.48 million. Amedisys had a net margin of 11.25% and a trailing twelve-month return on equity of 28.55%. The firm's quarterly revenue was up 16.3% on a year-over-year basis. During the same period last year, the business posted $1.34 EPS.
View Amedisys' earnings history.

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMED shares have decreased by 2.5% and is now trading at $166.26.
View which stocks have been most impacted by COVID-19.

Amedisys announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 4th 2021, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 1.2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's management believes its shares are undervalued.

Amedisys updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of $6.370-$6.490 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.960. The company issued revenue guidance of $2.23 million-$2.25 million, compared to the consensus revenue estimate of $2.32 billion.

10 Wall Street analysts have issued 1-year target prices for Amedisys' stock. Their forecasts range from $195.00 to $350.00. On average, they expect Amedisys' stock price to reach $269.55 in the next year. This suggests a possible upside of 62.1% from the stock's current price.
View analysts' price targets for Amedisys or view top-rated stocks among Wall Street analysts.

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Some companies that are related to Amedisys include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), R1 RCM (RCM), AMN Healthcare Services (AMN), LHC Group (LHCG), CorVel (CRVL), MEDNAX (MD), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of AMED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.07%), Vanguard Group Inc. (9.62%), Price T Rowe Associates Inc. MD (4.55%), JPMorgan Chase & Co. (3.88%), State Street Corp (2.53%) and Invesco Ltd. (2.53%). Company insiders that own Amedisys stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Wells Fargo & Company MN, BlackRock Inc., Invesco Ltd., First Trust Advisors LP, Price T Rowe Associates Inc. MD, Bank of America Corp DE, and PEAK6 Investments LLC. Company insiders that have sold Amedisys company stock in the last year include Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, and Scott G Ginn.
View insider buying and selling activity for Amedisys or view top insider-selling stocks.

AMED stock was acquired by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Amundi, Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Credit Suisse AG, Ensign Peak Advisors Inc, and Allianz Asset Management GmbH. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys or or view top insider-buying stocks.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMED stock can currently be purchased for approximately $166.26.

Amedisys has a market capitalization of $5.43 billion and generates $2.07 billion in revenue each year. The health services provider earns $183.61 million in net income (profit) each year or $6.11 on an earnings per share basis.

Amedisys employs 21,000 workers across the globe.

Amedisys was founded in 1982.

The official website for Amedisys is www.amedisys.com.

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at (225) 292-2031 or via email at [email protected]